Introduction
============

Differences in the incidence, diagnosis, management and survival among women and men have been reported in various malignancies, including colorectal, lung, head and neck cancer, and have contributed to the implementation of gender-specific recommendations in clinical oncology and health care ([@r1]). Urothelial carcinoma of the bladder (UCB) is the sixth most common malignancy and the second most common genitourinary cancer, accounting for 130,946 and 74,000 new cases, and 43,080 and 17,852 deaths in the European Union and the US in 2015, respectively ([@r2]).

Compared to their female counterparts, male patients are at a three to 4-fold higher risk of developing UCB ([@r3]). In addition, the UCB incidence increased 25% faster in men than in women during the past decade ([@r2]). Despite this gender disparity in the UCB epidemiology, there is substantial evidence that women present with more advanced disease stages at the primary diagnosis and may face worse outcomes compared to their male counterparts ([@r3]-[@r12]). In consequence, gender was included as prognosticator for UCB outcomes in various prediction tools ([@r13],[@r14]). However, more recently, controversial findings on gender-specific survival in UCB have been reported ([@r7]-[@r9],[@r12],[@r13],[@r15],[@r16]).

Elucidating the reasons for these gender-specific differences in the UCB incidence and survival may allow optimizing the uro-oncologic treatment and enhancing the quality of care among both genders. However, the specific causes remain currently a matter of debates. In general, gender-specific differences in outcomes of various malignancies seem to be multifactorial, comprising genetic, physiological and anatomic characteristics, heterogeneous exposure and responses to carcinogens, as well as treatment-related particularities ([@r1]). In UCB, gender-specific variabilities in the exposure and degradation of carcinogens, the sex-steroid hormone regulation, the anatomy of the bladder and pelvis, the diagnostic work-up, and the management of the disease ([@r17]-[@r26]), as well as discrepancies in the quality of care have turned into the focus of recent investigations ([@r27]-[@r29]).

In this non-systematic review we comprehensively summarize the most relevant studies on gender-specific differences on outcomes in non-muscle invasive, muscle-invasive as well as locally advanced and metastatic UCB. In addition, we summarize and discuss the underlying established and suggested biologic, anatomic and treatment-related mechanisms.

Female with bladder cancer: what is the difference?
===================================================

Gender-specific differences in urothelial carcinoma of the bladder (UCB) biologic characteristics
-------------------------------------------------------------------------------------------------

In UCB, female gender is associated with the presence of aggressive tumor biologic characteristics. Numerous studies consistently demonstrated that women present with more advanced UCB compared to men ([@r4]-[@r8],[@r10],[@r12]). Since an increasing pathologic tumor stage is a strong predictor for unfavorable outcomes in UCB ([@r7],[@r12],[@r30]), the established association of the female gender with more advanced disease is an accepted reason for the worse survival compared to male patients. In addition, female patients suffer more frequently from high-grade UCB ([@r3],[@r7],[@r8],[@r10]) and seem to present more frequently with multiple and larger tumors ([@r31]) as well as variant UCB histologies ([@r12]), which also may unfavorably impact outcomes .

Gender-specific differences in outcomes of non-muscle invasive bladder cancer (NMIBC)
-------------------------------------------------------------------------------------

[*Table 1*](#t1){ref-type="table"} summarizes selected studies on gender-specific differences in outcomes of NMIBC. Especially in high-grade UCB, numerous studies indicate an increased risk of disease recurrence or progression in women treated with TURB with or without intravesical immunotherapy or chemotherapy, compared to their male counterparts ([@r32],[@r34]-[@r36]). However, controversial findings have also been reported. In patients treated with Bacillus Calmette-Guérin (BCG) instillation therapy, some studies found no differences in outcomes between both genders ([@r33],[@r36],[@r37]).

###### Selected studies on gender-specific outcomes of bladder cancer patients treated with bladder preserving therapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Cohort \[patients (%)\]                                                          Period of treatment   Pathologic tumor stage \[patients (%)\]                              Treatment                     Intravesical instillation therapy \[patients (%)\]            Follow up (months)   Disease recurrence                     Disease progression                   Conclusion
  ----------------------------------- -------------------------------------------------------------------------------- --------------------- -------------------------------------------------------------------- ----------------------------- ------------------------------------------------------------- -------------------- -------------------------------------- ------------------------------------- -----------------------------------------------------------------------------------------------------------
  Fernandez-Gomez *et al*. ([@r32])   n=1,062: 706 (66.5) with primary NMIBC, and 356 (33.5) with recurrent NMIBC;\    1990--1999            pTa: 214 (20.2);\                                                    Primary TURB (all patients)   BCG induction (all patients)                                  69 (median)          UVA (f *vs*. m): HR =1.80, P\<0.01;\   UVA (f *vs*. m): HR =1.01, P=0.98;\   Negative impact of female gender on disease recurrence; no impact of gender on disease progression
                                      f: 111 (10.5), m: 951 (89.5)                                                                           pT1: 848 (79.8) plus concomitant;\                                                                                                                                                    MVA (f *vs*. m): HR =1.71, P\<0.01     MVA (f *vs*. m): NS                   
                                                                                                                                             cis: 80 (7.5);\                                                                                                                                                                                                                                                    
                                                                                                                                             gender distribution: NS                                                                                                                                                                                                                                            

  Boorjian *et al*. ([@r33])          n=1,021: with primary or recurrent NMIBC;\                                       1978--2006            pTa: 612 (59.9) \[f: 166 (62.6), m: 446 (59.0)\];\                   Re-TURB (all patients)        BCG induction (all patients)                                  ≥60                  MVA (m *vs*. f): HR =0.94, P=0.44      MVA (m *vs*. f): HR =1.18, P=0.33     No impact of female gender on disease recurrence and disease progression
                                      f: 265 (26.0), m: 756 (74.0)                                                                           pT1: 409 (40.1) \[f: 99 (37.4), m: 310 (41.0)\] plus concomitant;\                                                                                                                                                                                                 
                                                                                                                                             cis: 629 (62.0) \[f: 133 (50.2), m: 496 (65.6)\]                                                                                                                                                                                                                   

  Palou *et al*. ([@r34])             n=146: with primary NMIBC;\                                                      1985--1996            pT1: 146 (100.0) plus concomitant;\                                  TURB (all patients)           BCG induction (all patients)                                  104 (median)         UVA (f *vs*. m): HR =2.3, P\<0.01;\    UVA (f *vs*. m): HR =2.41, P=0.06;\   Negative impact of female gender on disease recurrence; no impact of female gender on disease progression
                                      f: 18 (12.3), m: 128 (87.7)                                                                            cis: 95 (65.1);\                                                                                                                                                                      MVA (f *vs*. m): NS                    MVA (f *vs*. m): NS                   
                                                                                                                                             gender distribution: NS                                                                                                                                                                                                                                            

  Chamie *et al*. ([@r35])            n=7,410: with primary or recurrent NMIBC;\                                       1992--2002            pTa: 2,398 (32.3);\                                                  NS                            NS                                                            ≥60                  MVA (f *vs*. m): HR =1.01, P=0.81      MVA (f *vs*. m): HR =1.23; P\<0.01    Negative impact of female gender on disease progression; no impact of female gender on disease recurrence
                                      f: 1,813 (24.5), m: 5,597 (75.5)                                                                       pT1: 4,258 (57.5);\                                                                                                                                                                                                                                                
                                                                                                                                             pTis: 754 (10.2);\                                                                                                                                                                                                                                                 
                                                                                                                                             gender distribution: NS                                                                                                                                                                                                                                            

  Kluth *et al*. ([@r36])             n=916: with primary NMIBC;\                                                      1996--2007            pT1: 916 (100.0) plus concomitant;\                                  TURB                          Single dose of MMC postoperatively:\                          43 (median)          MVA (f *vs*. m): HR =1.31, P=0.03      MVA (f *vs*. m): HR =1.25, P=0.32     Negative impact of female gender on disease recurrence; no impact of female gender on disease progression
                                      f: 190 (20.7), m: 726 (79.3)                                                                           cis: 53 (5.8) \[f: 13 (6.8), m: 40 (5.5)\]                                                         365 (39.8) \[f: 72 (37.9), m: 293 (40.4)\];\                                                                                                                    
                                                                                                                                                                                                                                                BCG induction: 234 (25.5) \[f: 52 (27.4), m: 182 (25.1)\];\                                                                                                     
                                                                                                                                                                                                                                                MMC induction: 35 (3.8) \[f: 11 (5.8), m: 24 (3.3)\]                                                                                                            

  Gontero *et al*. ([@r37])           n=2,451: 2,181 (89.0) with primary NMIBC and 270 (11.0) with recurrent NMIBC;\   1990--2011            pT1: 2451 (100.0) plus concomitant;\                                 TURB (all patients);\         BCG induction (all patients)                                  62 (median)          UVA (f *vs*. m): HR =1.07, P=0.32;\    UVA (f *vs*. m): HR =1.31, P=0.02;\   No impact of female gender on disease recurrence and disease progression
                                      f: 439 (17.9), m: 2,012 (82.1)                                                                         cis: 599 (24.4); gender distribution: NS                             plus Re-TURB: 935 (38.2)                                                                                         MVA (f *vs*. m): NS                    MVA (f *vs*. m): NS                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NMIBC, non-muscle invasive bladder cancer; f, female; m, male; NS, not stated; BCG, Bacillus Calmette-Guérin; UVA, univariable analysis; HR, hazard ratio; MVA, multivariable analysis; Re-TURB: repeat transurethral resection of the bladder; TURB, transurethral resection of the bladder; MMC, mitomycin.

Gender-specific differences in outcomes of urothelial carcinoma of the bladder (UCB) treated with radical cystectomy
--------------------------------------------------------------------------------------------------------------------

Evidence regarding gender-specific differences in UCB outcomes derives mainly from retrospective RC studies. [*Table 2*](#t2){ref-type="table"} presents an overview of selected studies on gender-specific differences in UCB patients treated with RC. The largest and most recent multi-center study by Kluth *et al.* comprised 8,102 UCB patients and found that female gender was an independent risk factor for reduced survival ([@r7]), which corroborates the findings of several previous reports ([@r9],[@r15],[@r22],[@r38],[@r40],[@r42]). Importantly, the most recent analyses included known confounders such as the pathologic tumor stage and the disease stage ([@r7],[@r9]). Thus, findings were adjusted for gender-specific discrepancies in the tumor stage at the primary diagnosis. Conversely, other authors found after adjustment for the performance status, comorbidities, pathologic tumor stage or treatment modalities no association between female gender and inferior survival ([@r8],[@r12],[@r16],[@r30],[@r39],[@r41],[@r43]). Inconsistent findings across different studies may be due to differences in cohort sizes, treatment modalities prior to RC, variable confounders that the studies have been adjusted for, as well as modifications in the surgical techniques and UCB management over time between older and more contemporary reports.

###### Selected studies on gender-specific outcomes of bladder cancer patients treated with radical cystectomy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Cohort \[patients (%)\]                        Period of treatment   Pathologic tumor stage and nodal status \[patients (%)\]   Adjuvant treatment \[patients (%)\]                   Follow-up (months)       Outcome                                                         Conclusion
  --------------------------- ---------------------------------------------- --------------------- ---------------------------------------------------------- ----------------------------------------------------- ------------------------ --------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Tilki *et al*. ([@r22])     n=583 \[f: 94 (16.1), m: 488 (83.7)\]          1979--2008            pT4: 583 (100.0); pN+: 312 (53.5);\                        CT: 240 (41.2);\                                      55 (median)              MVA (f *vs*. m): disease recurrence (HR =1.53, P\<0.01);\       Negative impact of female gender on cancer-specific mortality and disease recurrence
                                                                                                   gender distribution: NS                                    RT: 29 (5.0);\                                                                 cancer-specific mortality (HR =1.67, P\<0.01)                   
                                                                                                                                                              gender distribution: NS                                                                                                                        

  Tilki *et al*. ([@r38])     n=243 \[f: 50 (20.6), m: 193 (79.4%)\]         1979--2008            pTis: 243 (100.0); pN+: 22 (5.8);\                         NS                                                    38 (median)              MVA (f *vs*. m): disease recurrence (HR =1.58, P=0.17);\        Negative impact of female gender on cancer-specific mortality; no impact of female gender on disease recurrence
                                                                                                   gender distribution: NS                                                                                                                   cancer-specific mortality (HR =2.45, P=0.03)                    

  May *et al*. ([@r39])       n=521 \[f: 133 (25.5), m: 388 (74.5)\]         1992--2007            pT≤2: 216 (41.5) \[f: 57 (42.9), m: 159 (41.0)\];\         CT: 88 (16.9) \[f: 19 (14.3), m: 69 (17.8)\]          59 (median)              MVA (f *vs*. m): cancer-specific mortality (HR =1.35, P=0.05)   Negative impact of female gender on cancer-specific mortality
                                                                                                   pT3-4: 305 (58.5) \[f: 76 (57.1), m: 229 (59)\];\                                                                                                                                                         
                                                                                                   pN+: 174 (33.4) \[f: 41 (30.8), m: 133 (34.3)\]                                                                                                                                                           

  Otto *et al*. ([@r40])      n=2,483 \[f: 507 (20.4), m: 1,976 (79.6)\]     1989--2008            pT≤1: 708 (28.5) \[f: 125 (24.7), m: 583 (29.5)\];\        CT: 345 (13.9) \[f: 65 (12.8), m: 280 (14.2)\]        42 (median)              MVA (f *vs*. m): cancer-specific mortality (HR =1.26, P=0.01)   Negative impact of female gender on cancer-specific mortality
                                                                                                   pT2: 669 (27) \[f: 140 (27.6), m: 529 (26.8)\];\                                                                                                                                                          
                                                                                                   pT3: 841 (33.9) \[f: 197 (38.8), m: 644 (32.6)\];\                                                                                                                                                        
                                                                                                   pT4: 265 (10.7) \[f: 45 (8.9), m: 220 (11.1)\];\                                                                                                                                                          
                                                                                                   pN+: 640 (25.8) \[f: 138 (27.2), m: 502 (25.4)\]                                                                                                                                                          

  Kluth *et al*. ([@r7])      n=8,102 \[f: 1,605 (20.0), m: 6,497 (80.0)\]   1971--2012            pT0: 448 (5.5) \[f: 85 (5.3), m: 363 (5.6)\];\             CT: 1,654 (20.4) \[f: 330 (21.0), m: 1,324 (20.0)\]   41 (median)              MVA (f *vs*. m): disease recurrence (HR =1.08, P=0.11);\        Negative impact of female gender on cancer-specific mortality; no independent impact of female gender on disease recurrence
                                                                                                   pTa: 354 (4.4) \[f: 73 (4.5), m: 281 (4.3)\];\                                                                                            cancer-specific mortality (HR =1.17, P\<0.01)                   
                                                                                                   pTis: 650 (8.0) \[f: 119 (7.4), m: 531 (8.2)\];\                                                                                                                                                          
                                                                                                   pT1: 1,161 (14.3) \[f: 182 (11.0), m: 979 (15.0)\];\                                                                                                                                                      
                                                                                                   pT2: 1,984 (24.5) \[f: 394 (25.0), m: 1,590 (24.0)\];\                                                                                                                                                    
                                                                                                   pT3: 2,597 (32.1) \[f: 599 (37.0), m: 1,998 (31.0)\];\                                                                                                                                                    
                                                                                                   pT4: 908 (11.2) \[f: 153 (9.5), m: 755 (12.0)\];\                                                                                                                                                         
                                                                                                   pN+: 1,918 (23.7) \[f: 408 (25.0), m: 1,510 (23.0)\]                                                                                                                                                      

  Kaushik *et al*. ([@r41])   n=128 \[f: 37 (28.9), m: 91 (71.1)\]           1980--2005            pT4: 128; pN+: 53 (42.4) \[f: 9 (25.0), m: 44 (49.4)\]     CT\*: 37 (28.9) \[f: 7 (18.9), m: 30 (33.0)\]         126 (median)             MVA (m *vs*. f): all-cause mortality (HR 1.14, P=0.58);\        No impact of female gender on all-cause mortality and cancer-specific mortality
                                                                                                                                                                                                                                             cancer-specific mortality (HR 1.05, P=0.87)                     

  Soave *et al*. ([@r12])     n=517 \[f: 119 (23.0), m: 398 (77.0)\]         1996--2010            pT0: 51 (9.9) \[f: 12 (10.1), m: 39 (9.8)\];\              CT: 91 (17.6) \[f: 31 (26.1), m: 60 (15.1)\]          44 (median)              MVA (f *vs*. m): NS                                             No impact of female gender on disease recurrence and cancer-specific mortality
                                                                                                   pTa: 22 (4.3) \[f: 3 (2.6), m: 19 (4.8)\];\                                                                                                                                                               
                                                                                                   pTis: 47 (9.1) \[f: 5 (4.2), m: 42 (10.6)\];\                                                                                                                                                             
                                                                                                   pT1: 66 (12.8) \[f: 10 (8.4), m: 56 (14.1)\];\                                                                                                                                                            
                                                                                                   pT2: 96 (18.6) \[f: 28 (23.5), m: 68 (17.1)\];\                                                                                                                                                           
                                                                                                   pT3: 147 (28.4) \[f: 41 (34.5), m: 106 (26.6)\];\                                                                                                                                                         
                                                                                                   pT4: 88 (17.0) \[f: 20 (16.8), m: 68 (17.1)\];\                                                                                                                                                           
                                                                                                   pN+: 144 (27.9) \[f: 42 (35.3), m: 102 (25.6)\]                                                                                                                                                           

  Messer *et al*. ([@r9])     n=4,216 \[f: 890 (21.2), m: 3,326 (78.8)\]     1979--2008            pT≤1: 1,321 (31.3) \[f: 256 (28.9), m: 1,064 (32.1)\];\    CT: 993 (23.6) \[f: 194 (21.8), m: 799 (24.0)\]       32 (median)              MVA (f *vs*. m): disease recurrence (HR =1.16, P=0.03);\        Negative impact of female gender on disease recurrence and cancer-specific mortality
                                                                                                   pT2: 1,017 (24.1) \[f: 218 (24.6), m: 792 (23.9)\];\                                                                                      cancer-specific mortality (HR =1.27, P\<0.01)                   
                                                                                                   pT3-4: 1,884 (44.6) \[f: 413 (46.6), m: 1,460 (44.3)\];\                                                                                                                                                  
                                                                                                   pN+: 1,060 (25.5) \[f: 231 (26.4), m: 829 (25.2)\]                                                                                                                                                        

  Mitra *et al*. ([@r8])      n=828 \[f: 414 (50.0), m: 414 (50.0)\]         1971--2009            pT0,a,is: 172 (20.8) \[f: 86 (20.8), m: 86 (20.8)\];\      CT: 165 (19.9) \[f: 82 (49.7), m: 83 (50.3)\]         f: 146, m:103 (median)   MVA (f *vs*. m): NS                                             No impact of female gender on disease recurrence and cancer-specific mortality
                                                                                                   pT1:120 (14.5) \[f: 60 (14.5), m: 60 (14.5)\];\                                                                                                                                                           
                                                                                                   pT2: 196 (23.7) \[f: 98 (23.7), m: 98 (23.7)\];\                                                                                                                                                          
                                                                                                   pT3: 290 (35.0) \[f: 145 (35.0), m: 145 (35.0)\];\                                                                                                                                                        
                                                                                                   pT4: 50 (6.0) \[f: 25 (6.0), m: 25 (6.0)\];\                                                                                                                                                              
                                                                                                   pN+: 212 (50.0) \[f: 106 (25.6), m: 106 (25.6)\]                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*, neoadjuvant plus adjuvant chemotherapy. f, female; m, male; NS, not stated; CT, chemotherapy; RT, radiotherapy; MVA, multivariable analysis; HR, hazard ratio.

In summary, numerous retrospective RC series suggest that female gender is associated with unfavorable outcomes, even after adjustment for established confounders. However, these findings are inconsistent across the literature and some studies found no differences in outcomes among both genders. In the future, prospective studies are warranted to add more evidence on gender-specific differences in UCB outcomes.

Gender-specific differences in outcomes of locally advanced and metastatic urothelial carcinoma of the bladder (UCB)
--------------------------------------------------------------------------------------------------------------------

According to the TNM classification of tumors, the pathologic tumor substage 4a is defined by gender-specific anatomic particularities in UCB ([@r44]). In women, the tumor is invading the vagina or the uterus, whereas in men, the tumor is extending into the prostate ([@r44]). In pT4a UCB, controversial findings have been published regarding gender-specific differences in outcomes. One single-center study found no gender-specific differences in recurrence-free, cancer-specific and overall survival ([@r41]). However, according to several multi-center studies and Surveillance, Epidemiology and End Results (SEER) analyses, females seem to experience worse survival compared to men in pT4a UCB ([@r13],[@r22],[@r42]). Accordingly, in pT4a UCB patients following RC, female gender has been included as a strong predictor for reduced survival in several nomograms ([@r13],[@r14]). In pT4b UCB, the impact of the gender on survival has currently not been sufficiently investigated.

There is a paucity of data on gender and outcomes in metastatic UCB. A pooled analysis of phase II and III trials on first-line cisplatin-based chemotherapy showed similar tolerability, efficacy and outcomes in women and men ([@r45]). These findings have recently been supported by a SEER study, showing no gender-specific difference in the survival of 3,110 patients diagnosed with metastatic UCB from 1990 to 2010 ([@r46]). Correspondingly, gender was not an independent predictor for poor outcomes in metastatic UCB patients prior to cisplatin-based chemotherapy ([@r47]), and has therefore not been included in nomograms for predicting survival in metastatic UCB ([@r47],[@r48]).

Regional variations of gender-specific differences in outcomes of urothelial carcinoma of the bladder (UCB)
-----------------------------------------------------------------------------------------------------------

Results from an open cancer incidence and mortality database including 182 countries indicate that increased UCB-specific mortality in women compared to men is a common finding in the majority of countries ([@r49]). In 43% of countries, however, there was no gender-specific difference in the mortality among UCB patients ([@r49]). Interestingly, gender-specific disparities diminished over time in certain countries: especially in Germany, female patients experienced inferior outcomes in historical RC cohorts that were treated before the year 2000, whereas more contemporary cohorts show conflicting findings ([@r11]). Changes over time and regional variations of gender-specific UCB outcomes may be due to differences in UCB incidence and outcome registries ([@r50]), variable awareness of gender-specific differences in UCB behavior, different exposure to carcinogens as well as distinct health care systems with variant delays of diagnosis and treatment ([@r11]). However, further studies are needed to define the specific underlying reasons, thus contributing to our understanding of gender-specific differences in UCB outcomes.

Female with bladder cancer: why is there a difference?
======================================================

Anatomy
-------

UCB in general is a disease of the elderly and almost two-thirds of UCB patients are 65 years of age or older at diagnosis ([@r51]). Due to the high prevalence of benign prostatic enlargement with bladder outlet obstruction at this age, men typically have a thicker detrusor muscle compared to women, which may be a reason for a faster extravesical tumor growth in women ([@r52]). In addition, the embryonic development of the trigone and the posterior bladder neck from a common origin with the upper part of the vagina is possibly contributing to the more invasive extension pattern of UCB in women ([@r53]). The absence of the Fascia Denonvilliers and the anatomic site of the vagina and posterior bladder may represent a minor effective barrier for a continuous or lymphatic tumor spread in women ([@r9],[@r54]). Indeed, in men, the prostate and the prostatic urethra may impair the lymphovascular extension of the tumor ([@r55]). In women, the tumor extension to the urethra is facilitated by lymphatic vessels, which pass the lateral walls of the vagina and drain the bladder neck to the internal iliac lymph nodes ([@r52],[@r54],[@r55]).

Diagnostic work-up
------------------

The more aggressive biologic UCB features including the more advanced disease stages among women may be due to the fact that female patients experience a delay of the diagnostic work-up of the typical symptom of UCB, i.e., hematuria, and to be misdiagnosed with urinary tract infection ([@r25]). The clinical symptoms of UCB are similarly among both genders (i.e., mainly hematuria and lower urinary tract symptoms) ([@r23],[@r24]). According to several analyses, the interval from hematuria to diagnosis of UCB, however, is longer in women than in men, and an adequate work-up including imaging studies is less common in women than in men ([@r25],[@r56]). Moreover, females with hematuria are more likely to be diagnosed with urinary tract infection ([@r23]-[@r25]), and the probability of a referral to a urologist is significantly lower in female patients, compared to their male counterparts ([@r23]). As a delay in diagnosis and treatment of UCB is associated with more advanced disease stages at diagnosis, this indirectly also substantially contributes to gender-specific differences in outcomes, since more advanced stages are associated with inferior outcomes. A complete diagnostic work-up, including referral to a urologist, should consistently be encouraged to bypass any delay in diagnosing UCB in both genders. Indeed, the implementation of a protocol based electronic care coordination system decreased the time required for a complete hematuria evaluation, thus enhancing the quality of care ([@r57]), as well as potentially eliminating gender-specific UCB differences in the future.

Treatment
---------

In general, treatment strategies do not seem to differ between female and male UCB patients ([@r58]). Aggressive therapies (i.e., RC or radiation therapy) are offered equally to both genders according to a SEER database analysis of patients treated from 1992 to 1999 ([@r59]). Similarly, a population-based cancer registry study did not find differences in the usage of RC or radiation among both genders ([@r16]). Prior to RC, however, women seem to receive more frequently intravesical BCG immunotherapy, compared to their male counterparts ([@r31]). An explanation for this finding may be the BCG affiliated risk of prostatitis, presumably leading to a higher reluctance among the general urological practitioners in administering BCG in men. Conversely, other authors found that women were at a decreased probability to receive intravesical treatment before RC ([@r8]). However, in this large case-control study the authors did not specifically control for the administration of BCG ([@r8]).

At the time of RC, women are often older than men ([@r51]). Elderly patients are at an increased risk of cancer-specific mortality and receive less aggressive forms of treatment ([@r51]), which contributes to gender-specific differences in UCB outcomes. In addition, female patients are receiving more frequently incontinent urinary diversion compared to men ([@r60]), although recently increasing rates of continent diversion have been reported in women ([@r40]). Importantly, the type of urinary diversion may influence the postoperative morbidity and mortality ([@r60]). Gender-specific differences in the diversion may be due to possible voiding disturbances and concerns regarding the oncological safety of orthotopic urinary diversion in women ([@r5]), although a large amount of data provides reliable evidence of feasibility and local control in female UCB patients ([@r22],[@r38]).

Gender-specific discrepancies in the quality of surgical therapy have gained the attention of urologists during the last years. During TURB, female gender represents a risk factor for intraoperative bladder perforation ([@r61]), due to a thinner detrusor muscle ([@r52]). On the other hand, men are more prone to complications following TURB ([@r62]). The oncological quality of the RC is often measured by the soft tissue surgical margin status and the lymph node count, and several authors did not find differences in these variables between both genders ([@r7]-[@r9],[@r12]). Conversely, others showed a decreased probability of an adequate lymphadenectomy in women ([@r28]). Following RC, there seem to be relevant discrepancies in the perioperative quality of care among men and women. The 90-day mortality and perioperative complications seem to be elevated in female patients ([@r28],[@r29],[@r63]), which is underlined by a longer operative time and a longer in-hospital stay ([@r27],[@r28]) as well as a higher intraoperative blood loss and more frequent perioperative blood transfusions in women ([@r27],[@r28]). Importantly, perioperative blood transfusions have a negative impact on survival in UCB patients treated with RC ([@r64]). However, a contemporary SEER analysis of more than 5,000 patients showed that women are not at a higher risk of 90-day mortality compared to their male counterparts ([@r65]). Correspondingly, a single-center study found that female gender was not an independent predictor for low or high-grade complications after RC according the Clavien-Dindo classification ([@r66]).

Risk factors
------------

Cigarette smoking is the most relevant risk factor for the development of UCB accounting for 50% of new UCB cases and increasing the risk of UCB incidence by 2 to 6 fold independent of the gender ([@r67],[@r68]). In addition, particularly in female lifelong non-smokers, environmental tobacco smoke exposure may induce UCB development ([@r69]). A growing body of evidence suggests that smoking has a dose-dependent negative impact on survival in UCB patients treated with TURB and RC ([@r68],[@r70],[@r71]). Moreover, in smoking male patients, hypermethylation of tumor suppressor genes has been described, which is associated with unfavorable outcomes ([@r72]). On the other hand, smoking cessation for more than 10 years contributes to a prolonged survival in UCB patients treated with TURB or RC ([@r68],[@r70],[@r71]). Currently, the gender-specific effect of smoking on UCB outcomes remains controversial. Particularly in men, smoking may have a detrimental effect on recurrence-free survival following TURB ([@r73]). In recurrent NMIBC patients treated with TURB with or without intravesical therapy, women with a history of tobacco use had an increased risk of disease progression ([@r74]). In contrast, other studies determined that male patients treated with TURB might have worse overall survival compared to women ([@r75],[@r76]). In MIBC patients treated with RC, female smokers are at a higher risk of experiencing unfavorable outcomes, compared to their male counterparts ([@r71]). However, other authors found that the gender and smoking did not significantly interact for predicting cancer-specific mortality following RC ([@r77]). To date, still more men than women are smokers worldwide, and, in general, smoking prevalence has been constantly decreasing among both genders during the last three decades ([@r78]). However, tobacco use in women is rising, with female smoking being predicted to double between 2005 and 2025, while simultaneously declining in men ([@r79]), potentially contributing to gender-specific disparities in UCB incidence and survival. However, gender-specific differences in the risk of developing UCB seem to persist after adjustment for tobacco use ([@r80]). For example, data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and National Lung Cancer Screening Trial cohorts suggest that there remains a gender-specific disparity in the incidence of UCB in subgroups of equal smoking intensity ([@r81]). Independent of the gender, urologists should endeavor to counsel patients on smoking cessation, implementing tobacco screening in every day clinical practice, advising patients regarding the deleterious effects of smoking on UCB development and outcomes, as well as the beneficial influence of smoking cessation ([@r70]).

Approximately 10% of new UCB cases may be related to occupational risk factors ([@r82]). Particularly, workers processing aluminum, metal, aromatic amines, polycyclic aromatic hydrocarbons, oil, leather, dye and paint are at a high risk of development of UCB, leading to specific workplace health and safety regulations in various countries ([@r82]). Interestingly, occupational risk factors have mainly not been considered in gender-specific UCB incidence and outcome analyses thus far ([@r11]). Therefore, future studies are warranted to define the gender-specific impact on occupational exposure on the risk of UCB incidence and survival. A large population-based case-control study found that women using permanent hair dyes were at an increased risk of developing UCB. Especially women with N-acetyltransferase (NAT)-2 slow acetylation phenotype were at the highest UCB risk ([@r83]). In contrast, men using hair dyes are not at an increased risk of developing UCB ([@r83]).

Chronic inflammatory reactions seem to influence carcinogenesis, as observed in various malignancies. In bladder cancer, the infection with schistosomas is strongly associated with the risk of squamous carcinoma of the bladder, and there seem to be gender-specific differences in the prevalence of schistosoma infection ([@r84]). In addition, other pathogens inducing inflammatory reactions may have an impact on the risk of developing UCB. For example, an elevated risk of UCB development among patients with a history of gonorrhea ([@r85]) and Human papillomavirus infection ([@r86]) was reported, however, the current evidence is inconsistent ([@r87]). In general, women suffer more frequently from urinary tract infections and harbor different urinary pathogens compared to men. Similarly, UCB patients have different microorganisms compared to non-UCB patients. However, it remains unclear, whether variable frequencies of urinary tract infections and different distributions of urinary pathogens among both genders may be associated with a distinct UCB risk ([@r11]).

Radiation therapy of pelvic cancers in men and women, including prostate cancer as well as cervical and endometrial cancer, increases the risk of UCB development ([@r88]). In addition, cyclophosphamide-containing chemotherapy is associated with an increased UCB risk ([@r89]). However, it remains currently unclear, whether women are more susceptible to UCB development after radiation or chemotherapy compared to men.

Degradation of carcinogens
--------------------------

Although, to date, it remains mainly speculative, there might be gender-specific differences in the degradation of carcinogens at the molecular level ([@r90]), subsequently influencing gender-specific discrepancies in the UCB incidence and mortality. Different hydroxylation, acetylation and glucuronidation pathways, which include various enzymes such as uridine-diphosphoglucuronosyltransferase (UGT) and NAT-2, play an essential role in the degradation of aromatic amines ([@r11],[@r90],[@r91]). In the urothelium, androgen receptor (AR)-mediated signaling influences UGT expression ([@r11],[@r90]). Thus, urothelial UGT expression may substantially vary among both genders. Although, in general, a slow acetylation status of NAT-2 is correlated with an elevated UCB risk, a recent meta-analysis did not find associations between the combined effect of NAT-2 slow phenotypes and gender ([@r91]). Glutathione-S-transferase M1 (GSTM1) is an enzyme that degrades various substances including certain carcinogens by conjugation to glutathione ([@r90]). Providing further evidence that a variable GSTM1 expression among both genders contributes to gender-specific differences in the UCB susceptibility, a population-based case-control study determined that smoking women with a non-functioning GSTM1 are at an elevated bladder cancer risk, compared to men ([@r11]).

Taken together, there are findings suggesting disparities in the carcinogen degradation between women and men. However, future investigations are warranted to verify these potential gender-specific differences.

Sex-steroids
------------

Since postmenopausal women are at a higher risk for developing UCB compared to premenopausal women ([@r92]), UCB is suggested being a sex-hormone-dependent disease. In addition, women with an older age at the menarche, parity, as well as combined hormone replacement therapy with estrogen plus progestin seem to be at a lower risk for UCB development ([@r11],[@r17],[@r93]). Conversely, the supposed protective effect of postmenopausal hormone replacement therapy of estrogen and progesterone was shown to forfeit significance in treatment-periods lasting ≥10 years ([@r17]), whereas other authors did not find any impact on the development of UCB ([@r93]). To date, numerous studies have indicated a potential role of androgens and estrogens as well as the associated receptors in influencing UCB development and the course of the disease ([@r18]-[@r21],[@r90]).

The AR is a steroid hormone receptor, which is activated by the androgens testosterone and dihydrotesterone (DHT) ([@r94]). Following the binding of androgens, the AR translocates from the cytoplasm to the nucleus and controls the transcription of various genes. In the absence of androgens, signaling initiated by other receptors, e.g., epidermal growth factor receptor (EGFR), may facilitate the activation of AR ([@r94]). In UCB, the AR expression is decreasing with increasing pathologic stage, with 88.9% of pTa UCB and 0% of pT3 UCB expressing the AR, respectively ([@r20]). In addition, co-regulators of the AR enabling the formation of the AR transcriptional complex are expressed in 85% to 100% of UCB specimens ([@r95]). Moreover, high-risk UCB may lose the expression of 5-α-reductase, leading to an impaired conversion of testosterone to the more potent DHT ([@r11]). Increased androgen-dependent susceptibility of the urothelium to carcinogens, impaired degradation of carcinogens by androgen-dependent pathways or direct oncogenic effects of androgens presumably represent underlying molecular mechanisms, by which androgens promote UCB development and influence the course of disease ([@r19]). These hypotheses are mainly supported by animal studies. For example, the castration of transgenic bladder cancer-developing mice subsequently decreased the tumor size, compared to non-castrated mice and castrated mice treated with DHT, whereas AR knock-out hampered nitrosamine-induced bladder cancer in mice ([@r11]). In addition, AR signaling may promote UCB development by down-regulation of the expression of UGT in the urothelium ([@r96]). Importantly, the AR may influence various other signaling pathways to promote carcinogenesis ([@r94]), including the interaction with β-catenin, cyclin-d and EGFR, which have been shown to be associated with an aggressive UCB biologic behavior ([@r97]-[@r99]). Still, anti-androgenic therapies usually are not applied in the treatment of UCB patients.

The expression of the estrogen receptor (ER)-β is increasing with advancing pathologic tumor stage and higher grading ([@r21]), with 53% of pTa UCB and 75% of pT4 tumors, as well as 58% of WHO Grade 1 and 2 tumors and 70% of Grade 3 tumors expressing the isoform ER-β, respectively ([@r100]). In contrast, the ER-α is rarely expressed in the urothelium and not associated with the UCB behavior ([@r18],[@r21]). The role of the progesterone receptor A in UCB, which is expressed in the squamous epithelium of the urethra, is currently not completely understood ([@r18]). Data of in vitro and animal experiments suggest that anti-estrogen treatment (e.g., tamoxifen) may result in a reduction of UCB incidence following carcinogen exposure ([@r101]). However, anti-estrogens have thus far not been regularly included in studies on therapies of UCB in women and men.

On the genetic level, it has been shown that various single-nucleotide polymorphisms on chromosome 8q24, especially the PSCA gene, are associated with an increased UCB risk. In its promoter region, the PSCA gene contains an androgen response element. Similarly to prostate cancer, the loss of AR reactivity may induce an androgen-independent status facilitating the metastatic spread. Speculatively, the lower androgen levels in women may cause an earlier loss of AR reactivity, subsequently leading to the more aggressive tumor biology in female UCB patients ([@r11],[@r19]).

In summary, the sex-steroids and their corresponding receptors may influence the carcinogenesis of UCB at various levels. Although, to date, targeting of the sex-steroid signaling, has not been routinely included in the treatment of UCB, the gender-specific differences in the circulating sex-hormones and their related receptors among women and men may represent an opportunity for the emerging targeted therapies in UCB, presumably allowing a more tailored treatment among both genders in the future.

Conclusions
===========

Men and women have distinct differences in UCB incidence, behavior and outcomes. While men are at a higher risk of UCB development, there is evidence indicating that women present with more aggressive tumor biologic features and experience worse outcomes. The disparity between women and men is proposed to be a multifactorial result of differential exposures to environmental factors, such as carcinogens (i.e., tobacco and chemicals), as well as genetic, anatomic, hormonal, and societal factors, as well as quality of care and regional variations. Finally, the complexity of distinguished gender-specific variations and their coherence influencing UCB outcomes are yet not entirely understood. Nevertheless, it is important that urologists and general medical practitioners are already aware of these gender-specific disparities in UCB outcomes today, to improve the diagnostic workup and optimize treatment and outcomes, especially in women.
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